RECEIVED
CENTRAL FAX CENTER
JUL 21 2010

Amendments To The Claims

The listing of claims presented below will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (previously presented) A compound which is 5'-lauric acid ester of riboflavin.

2- 5 (canceled)

6. (previously presented) An oil suspension preparation comprising as a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:



Formula II.

7. (previously presented) The suspension preparation according to claim 6, wherein camellia oil is added and the ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	50 - 150 mg,
Ethyl oleate	0.1 - 1 ml, and
Camellia oil	0-1 ml.

8. (previously presented) The suspension preparation according to claim 7, wherein

the preferable ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, and
Camellia oil	0.5 ml.

9-11. (canceled)

12. (previously presented) A method of therapeutically treating either an ariboflavinosis condition, a digestive tract catarrh, or a persistent oral ulcer of an animal comprising the steps of:

obtaining a suspension preparation containing a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:



Formula II; and

administering a portion of the suspension preparation to the animal.

13-20. (canceled)

21. (previously presented) The method of claim 12 further comprising the step of: subjecting the animal to a chemotherapy regimen.

22. (currently amended) The method of claim 21 wherein the chemotherapy regimen is

selected from the group consisting of high-dose methotrexate (HDMTX) chemotherapy, and DA (daunorubicin) and ~~CODPL~~ cyclophosphamide oncovin daunomycin prednione l-asparaginase (CODPL) chemotherapy.

23. (previously presented) The method of claim 12 wherein the administering step comprises injecting the portion of the suspension preparation into the animal.

24. (currently amended) The method of claim 12 wherein the administering step comprises injecting ~~intermuscularly~~ intramuscularly the portion of the suspension preparation into the animal.

25. (previously presented) The method of claim 12 wherein the administering step comprises feeding the portion of the suspension preparation to the animal.

26. (previously presented) The method of claim 12, wherein the suspension preparation is used to treat the ariboflavinosis condition.

27. (previously presented) The method of claim 12, wherein the suspension preparation is used to treat digestive tract catarrh caused by bone marrow transplantation, leukemia or chemotherapy.

28. (previously presented) The method of claim 12, wherein the suspension preparation is used to treat persistent oral ulcer.

29. (previously presented) The method of claim 12, wherein the animal is a rat.

30. (previously presented) The method of claim 12, wherein the animal is a human.

31. (previously presented) The method of claim 12, wherein the suspension preparation further contains camellia oil.

32. (previously presented) The method of claim 29, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	50 - 150 mg;
Ethyl oleate	0.1 - 1 ml; and
Camellia oil	0-1 ml.

33. (previously presented) The method of using the compound of claim 31, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, and
Camellia oil	0.5 ml.

34. (previously presented) A compound which is 5'-lauric acid ester of riboflavin for intramuscular injection.